Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Adriana Rogozea"'
Autor:
Silvia Schmidtova, Katarina Kalavska, Veronika Liskova, Jana Plava, Svetlana Miklikova, Lucia Kucerova, Miroslava Matuskova, Lucia Rojikova, Zuzana Cierna, Adriana Rogozea, Heiko Konig, Costantine Albany, Michal Mego, Michal Chovanec
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 8, p 4263 (2021)
The majority of patients with testicular germ cell tumors (GCTs) can be cured with cisplatin-based chemotherapy. However, for a subset of patients present with cisplatin-refractory disease, which confers a poor prognosis, the treatment options are li
Externí odkaz:
https://doaj.org/article/f36766710861418fba3321b46fa76f98
Autor:
Svetlana Miklikova, Katarina Kalavska, Lucia Rojikova, Michal Mego, Adriana Rogozea, Michal Chovanec, Silvia Schmidtova, Miroslava Matuskova, Heiko Konig, Jana Plava, Zuzana Cierna, Veronika Liskova, Lucia Kucerova, Costantine Albany
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 4263, p 4263 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 8
International Journal of Molecular Sciences
Volume 22
Issue 8
The majority of patients with testicular germ cell tumors (GCTs) can be cured with cisplatin-based chemotherapy. However, for a subset of patients present with cisplatin-refractory disease, which confers a poor prognosis, the treatment options are li
Autor:
Lakshmi Reddy Palam, Adriana Rogozea, Larry D. Cripe, Hamid Sayar, Baskar Ramdas, H. Scott Boswell, Katie J Sargent, Reuben Kapur, Silvia Marino, Daniela N. Petrusca, Rajasubramaniam Shanmugam, Sravanti Rangaraju, Heiko Konig, G. David Roodman
Publikováno v:
Blood. 132:3949-3949
Enhanced blast clearance/remission followed for relapsed/refractory AML patients, in whose blasts were annotated by mutant Flt3 in company with additional TET2 mutation, when a combination of Sorafenib/Vorinostat was supplemented by Bortezomib (Sayar
Publikováno v:
Cancer Research. 78:2427-2427
Background: FLT3/ITD+ AML is a highly aggressive form of leukemia that carries a dismal prognosis. Evidence suggests that this poor outcome is due to the survival of a subset of leukemic cells (LCs) that elude therapy and survive in hypoxic niches of
Publikováno v:
Experimental Hematology. 53:S88
Publikováno v:
Blood. 128:1579-1579
Background: FLT3/ITD mutated AML is characterized by short remission duration and high relapse rates due to the survival of a small fraction of leukemic cells (LCs) that outlive initial therapy. There is compelling evidence that the hypoxic niche in
Autor:
Chen, Fangli *, Wu, Xue *, Adriana, Rogozea *, Guo, Bin, Boswell, H. Scott, Calin, George A. *, Ivan, Mircea *, Konig, Heiko
Publikováno v:
In Blood 29 November 2018 132 Supplement 1:2631-2631